Among the class for Lp-PLA2 inhibitors, Darapladib (6) has been the most promising, advancing into phase III clinical trials originally as a therapeutic for atherosclerosis but failing to meet efficacy requirements (Woolford et al., 2016). This evidence concerns the gene PLA2G7 and atherosclerosis.